Other Targets Overview

Prelude currently has multiple additional drug discovery programs that are focused on the identification of novel small molecule inhibitors targeting key intervention points in signaling and gene transcription pathways. These targets were selected based on the preclinical and/or clinical validation of their role in driving oncological resistance. The effort to identify, validate and invent inhibitors of these driver mechanisms is the primary mission of the discovery team at Prelude.